MoonLake Immunotherapeutics Reports
Second Quarter 2024 Financial Results and Announces a Capital
Markets Update for September 11
- Initiated Phase 3 VELA program of
the Nanobody® sonelokimab in hidradenitis suppurativa (“HS”), with
topline results anticipated as of mid-2025
- Secured positive feedback from both
U.S. Food and Drug Administration (“FDA”) and the E.U. European
Medicines Agency (“EMA”) on the regulatory path for the Phase 3
program of the Nanobody® sonelokimab in psoriatic arthritis (“PsA”)
and outlined the clinical plan with topline results anticipated in
end-2026
- Ended the quarter with $519.8
million in cash, cash equivalents and short-term marketable debt
securities, expected to support a roadmap rich in potential
catalysts whilst providing a cash runway to the end of 2026
- Capital Markets Update to be held
on Wednesday, September 11 – to provide an update on market
opportunity and trial execution
ZUG, Switzerland, August 7,
2024 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the
“Company”), a clinical-stage biotechnology company focused on
creating next-level therapies for inflammatory diseases, today
announced its financial results for the second quarter of 2024.
MoonLake continues to make significant progress in advancing its
investigational Nanobody® sonelokimab in a number of dermatological
and rheumatological inflammatory indications.
Following positive top-line results from its
global Phase 2 MIRA trial announced last year, the Company
initiated its global Phase 3 VELA program during the quarter to
evaluate sonelokimab for a total of 52 weeks in an estimated total
of 800 patients with moderate-to-severe HS. Management anticipates
topline results of the 16 weeks primary endpoint as of mid-2025.
The initiation of an additional Phase 3 study in adolescents with
HS, the VELA TEEN trial, is on track for enrollment of the first
patients around year-end.
MoonLake also received positive regulatory
feedback from both the FDA and the EMA during the quarter which
clarifies the path for its Phase 3 IZAR program in PsA. IZAR-1 will
focus on bio-naïve patients* and radiographic progression whilst
IZAR-2 will focus on TNF-IR patients**. The IZAR program will
feature risankizumab as a reference arm and is expected to enroll
around 1,500 patients, starting in the fourth quarter of 2024.
Preparations for the initiation of additional
Phase 2 trials of sonelokimab in palmo-plantar pustulosis (“PPP”),
radiographic and non-radiographic axial spondyloarthritis (“axSpA”)
are ongoing and progressing according to plan for an expected
enrollment of first patients before the end of the year.
Dr. Jorge Santos da Silva, Chief
Executive Officer of MoonLake Immunotherapeutics, said:
“This quarter saw us take important steps towards registration as
we enrolled the first patients into the HS Phase 3 trials for our
Nanobody® sonelokimab. By the end of the of the year we expect to
have Phase 3 programs underway in both HS and PsA, two major
inflammation & immunology indications. Given that HS most
commonly manifests in young adults, we also plan to initiate a
Phase 3 trial in adolescent HS which we expect to be the first
dedicated clinical trial focused on the adolescent HS population.
Our additional trials in PPP, axSpA and PsA are expected to provide
further opportunities for MoonLake. Our team continues to grow in a
carefully managed way, adding new capabilities to support our
maturing status. We look forward to providing further updates on
progress at our Capital Markets Update in September.”
Q2 highlights (including post-period
end)
- Initiated Phase 3 VELA program of
the Nanobody® sonelokimab in patients with moderate-to-severe HS;
VELA is the first Phase 3 program in HS to use the higher clinical
response (HiSCR75); topline primary endpoint readout (week 16)
expected as of mid-2025
- Received positive feedback from
both the FDA and EMA on the regulatory path for IZAR, the second
Phase 3 program to be initiated by MoonLake this year, that
outlined the development plan for the program to evaluate
sonelokimab for a total of 52 weeks in patients with active PsA;
two trials planned – one focusing on bio-naïve patients* and
radiographic progression (IZAR-1) and the other on TNF-IR
patients** (IZAR-2) with topline results anticipated by
end-2026
- Presented Week 12 efficacy and
safety outcomes from the Phase 2 ARGO trial in PsA patients at the
European Alliance of Associations for Rheumatology Congress (EULAR)
congress in Vienna
- Signed a three-year technology
partnership with Komodo Health to advance research on inflammatory
skin and joint conditions and presented initial data from this
partnership, indicating that at least two million Americans have
been diagnosed with HS as of 2023, highlighting a significant unmet
need and impact on healthcare systems, and a potential market
opportunity exceeding $10bn by 2035
* Patients without previous exposure to biologics
** Patients with an inadequate response to TNF
inhibitors
First quarter 2024 financial results
As of June 30, 2024, MoonLake held cash,
cash equivalents and short-term marketable debt securities of
$519.8 million. Research and development expenses for the quarter
ended June 30, 2024, were $23.7 million, compared to $13.0
million in the previous quarter. The increase was primarily due to
expenses incurred to initiate new clinical trials. General and
administrative expenses for the quarter ended June 30, 2024
were $6.9 million, similar to the $6.8 million incurred in the
previous quarter.
Matthias Bodenstedt, Chief Financial
Officer at MoonLake Immunotherapeutics, said: “MoonLake is
in full execution mode and on track for many important data reads
in 2025, including the anticipated primary readout of the Phase 3
HS VELA program. With over $500 million in cash, cash equivalents
and short-term marketable debt securities on the balance sheet, we
remain well capitalized and our runway guidance to the end of 2026
remains unchanged. Recent market feedback confirms the significant
unmet need and commercial opportunity in our focus indications, and
we believe that Sonelokimab is uniquely positioned to capture this
opportunity.”
Capital Markets Update on Wednesday,
September 11
MoonLake will be hosting a Capital Markets
Update for investors and analysts on Wednesday, September 11. The
live webcast will provide updates from MoonLake’s executive team on
the ongoing clinical trials and the Company’s view on the market
opportunity featuring insights from recent claims data
analyses.
Important upcoming anticipated events
for MoonLake:
- Q3-2024: Hosting of a Capital Markets Update on September
11
- Q4-2024: Initiation of the Phase 3 IZAR program in PsA
- 2H-2024: Initiation of additional Phase 2 trials as announced
for dermatology and rheumatology indications
- Around year-end 2024: Initiation of Phase 3 VELA TEEN program
in adolescent HS
- As of mid-2025: Topline primary endpoint readout for Phase 3
VELA program in HS
Upcoming banking and medical
conferences
- European Society of Dermatological
Research Annual Meeting, September 4-7, Lisbon, Portugal
- International Congress on
Spondyloarthritides, September 5-7, Gent, Belgium
- Cantor Annual Healthcare
Conference, September 17-19, New York, US
- European Academy of Dermatology and
Venereology (EADV) Congress, September 25-28, Amsterdam, The
Netherlands
- Symposium on Hidradenitis
Suppurativa Advances (SHSA), November 1-3, Texas, USA
- American College of Rheumatology
(ACR) Conference, November 14-19 Washington DC, USA
- Jefferies London Healthcare
Conference, November 19-21, 2024, London, UK
- Citi’s 19th Annual BioPharma
Conference, December 3-5, Boston, US
-Ends-
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage
biopharmaceutical company unlocking the potential of sonelokimab, a
novel investigational Nanobody® for the treatment of inflammatory
disease, to revolutionize outcomes for patients. Sonelokimab
inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F,
and IL-17F/F dimers that drive inflammation. The company’s focus is
on inflammatory diseases with a major unmet need, including
hidradenitis suppurativa and psoriatic arthritis – conditions
affecting millions of people worldwide with a large need for
improved treatment options. MoonLake was founded in 2021 and is
headquartered in Zug, Switzerland. Further information is available
at www.moonlaketx.com.
About Sonelokimab
Sonelokimab (M1095) is an investigational ~40
kDa humanized Nanobody® consisting of three VHH domains covalently
linked by flexible glycine-serine spacers. With two domains,
sonelokimab selectively binds with high affinity to IL-17A and
IL-17F, thereby inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F
dimers. A third central domain binds to human albumin, facilitating
further enrichment of sonelokimab at sites of inflammatory
edema.
Sonelokimab is being assessed in two lead
indications, hidradenitis suppurativa (HS) and psoriatic arthritis
(PSA), and the Company is pursuing other indications in dermatology
and rheumatology.
For HS, sonelokimab is being assessed in two
Phase 3 trials, VELA-1 and VELA-2 following the successful outcome
of MoonLake’s end-of-Phase 2 interactions with the FDA and as well
as positive feedback from its interactions with the EMA announced
in February 2024. In October 2023, the full dataset from the Phase
2 MIRA trial at 24 weeks (NCT05322473) showed that maintenance
treatment with sonelokimab led to further improvements in
Hidradenitis Suppurativa Clinical Response (HiSCR)75 which is a
higher measure of clinical response versus the HiSCR50 measure used
in other clinical trials, setting a landmark milestone and other
clinically relevant outcomes. Prior to this, in June 2023, topline
results of the MIRA trial at 12 weeks showed that the trial met its
primary endpoint, HiSCR75.
For PsA, Phase 3 initiation is anticipated in Q4
2024 following the announcement in March 2024 of the full dataset
from the global Phase 2 ARGO trial evaluating the efficacy and
safety of the Nanobody® sonelokimab over 24 weeks in patients with
active PsA. Significant improvements were observed across all key
outcomes, including approximately 60% of patients treated with
sonelokimab achieving an ACR50 response at week 24. This followed
the positive top-line results in November 2023, where the trial met
its primary endpoint with a statistically significant greater
proportion of patients treated with either sonelokimab 60mg or
120mg (with induction) achieving an American College of
Rheumatology (ACR) 50 response compared to those on placebo at week
12. All key secondary endpoints in the trial were met for the 60mg
and 120mg doses with induction.
A Phase 2 trial is expected to be initiated in
palmo-plantar pustulosis (PPP), a debilitating disease affecting a
significant number of patients. In addition, a Phase 3 trial is
expected to initiate in adolescent HS, a disease that typically
begins at this early stage of a patient’s life, and also the period
in which irreversible damage and inflammatory remission is most
critical.
Sonelokimab will also be assessed for
seronegative spondyloarthritis with a Phase 2 trial in radiographic
and non-radiographic axial spondyloarthritis (axSpA) expected to
start in 2024. The trials will feature an innovative design
complementing traditional clinical outcomes with modern imaging
techniques.
Sonelokimab has also been assessed in a
randomized, placebo-controlled Phase 2b trial (NCT03384745) in 313
patients with moderate-to-severe plaque-type psoriasis. High
threshold clinical responses (Investigator’s Global Assessment
Score 0 or 1, and Psoriasis Area and Severity Index 90/100) were
observed in patients with moderate-to-severe plaque-type psoriasis.
Sonelokimab was generally well tolerated, with a safety profile
similar to the active control, secukinumab (Papp KA, et al. Lancet.
2021; 397:1564-1575).
In an earlier Phase 1 trial in patients with
moderate-to-severe plaque-type psoriasis, sonelokimab has been
shown to decrease (to normal skin levels) the cutaneous gene
expression of pro-inflammatory cytokines and chemokines (Svecova D.
J Am Acad Dermatol. 2019;81:196–203).
About Nanobodies®
Nanobodies® represent a new generation of
antibody-derived targeted therapies. They consist of one or more
domains based on the small antigen-binding variable regions of
heavy-chain-only antibodies (VHH). Nanobodies® have a number of
potential advantages over traditional antibodies, including their
small size, enhanced tissue penetration, resistance to temperature
changes, ease of manufacturing, and their ability to be designed
into multivalent therapeutic molecules with bespoke target
combinations.
The terms Nanobody® and Nanobodies® are
trademarks of Ablynx, a Sanofi company.
About the VELA program
The VELA program is expected to enroll 800
patients across two similarly designed Phase 3 trials (VELA-1 and
VELA-2) with the aim to evaluate the efficacy and safety of the
Nanobody® sonelokimab, administered subcutaneously, in adult
patients with active moderate-to-severe hidradenitis suppurativa.
Similar to the design of the landmark Phase 2 MIRA trial, the
primary endpoint of the program is the percentage of participants
achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75),
defined as a ≥75% reduction in total abscess and inflammatory
nodule (AN) count with no increase in abscess or draining tunnel
count relative to baseline. The trial will also evaluate a number
of secondary endpoints, including the proportion of patients
achieving Hidradenitis Suppurative Clinical Response (HiSCR50), the
change from baseline in International Hidradenitis Suppurativa
Severity Score System (IHS4), the proportion of patients achieving
a Dermatology Life Quality Index (DLQI) total score of ≤5, and the
proportion of patients achieving at least 30% reduction from
baseline in Numerical Rating Scale (NRS30) in the Patient’s Global
Assessment of Skin Pain (PGA Skin Pain). Further details are
available under NCT06411379 and NCT06411899 at
www.clinicaltrials.gov.
About the MIRA trial
The MIRA trial (M1095-HS-201) is a global,
randomized, double-blind, placebo-controlled trial to evaluate the
efficacy and safety of the Nanobody® sonelokimab, administered
subcutaneously, in the treatment of adult patients with active
moderate to severe hidradenitis suppurativa. The trial recruited
234 patients, with the aim to evaluate two different doses of
sonelokimab, with placebo control and adalimumab as an active
control reference arm. The primary endpoint of the trial is the
percentage of participants achieving Hidradenitis Suppurativa
Clinical Response 75 (HiSCR75), defined as a ≥75% reduction in
total abscess and inflammatory nodule (AN) count with no increase
in abscess or draining tunnel count relative to baseline. The trial
also evaluated a number of secondary endpoints, including the
proportion of patients achieving HiSCR50, the change from baseline
in International Hidradenitis Suppurativa Severity Score System
(IHS4), the proportion of patients achieving a Dermatology Life
Quality Index (DLQI) total score of ≤5, and the proportion of
patients achieving at least 30% reduction from baseline in
Numerical Rating Scale (NRS30) in the Patient’s Global Assessment
of Skin Pain (PGA Skin Pain). Further details are available on:
https://www.clinicaltrials.gov/ct2/show/NCT05322473
About the ARGO trial
The ARGO trial (M1095-PSA-201) is a global,
randomized, double-blind, placebo-controlled trial to evaluate the
efficacy and safety of the sonelokimab, administered
subcutaneously, in the treatment of adult patients with active PsA.
The trial recruited 207 patients, with the aim to evaluate
different doses of sonelokimab, with placebo control and adalimumab
as an active reference arm. The primary endpoint of the trial is
the percentage of participants achieving ≥50% improvement in signs
and symptoms of disease from baseline, compared to placebo, as
measured by the American College of Rheumatology (ACR) 50 response.
The trial also evaluated a number of secondary endpoints, including
improvement compared to placebo in ACR70, complete skin clearance
as measured by at least a 100% improvement in the Psoriasis Area
and Severity Index, physical function as measured by the Health
Assessment Questionnaire-Disability Index, enthesitis as measured
by the Leeds Enthesitis Index and pain as measured by the Patients
Assessment of Arthritis Pain. Further details are available on:
https://clinicaltrials.gov/ct2/show/NCT05640245
About Hidradenitis Suppurativa
Hidradenitis suppurativa is a severely
debilitating chronic skin condition resulting in irreversible
tissue destruction. HS manifests as painful inflammatory skin
lesions, typically around the armpits, groin, and buttocks. Over
time, uncontrolled and inadequately treated inflammation can result
in irreversible tissue destruction and scarring. The disease
affects 0.05–4.1% of the global population, with three times more
females affected than males. Real-world data indicates that at
least 2 million Americans have been diagnosed with HS as of 2023,
highlighting a significant unmet need and impact on healthcare
systems, and a market opportunity exceeding $10bn by 2035. Onset
typically occurs in early adulthood and HS has a profound negative
impact on quality of life, with a higher morbidity than other
dermatologic conditions. There is increasing scientific evidence to
support IL-17A- and IL-17F-mediated inflammation as a key driver of
the pathogenesis of HS, with other identified risk factors
including genetics, cigarette smoking, and obesity.
About Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic and
progressive inflammatory arthritis associated with psoriasis
primarily affecting the peripheral joints. The clinical features of
PsA are diverse, involving pain, swelling, and stiffness of the
joints, which can result in restricted mobility and fatigue. PsA
occurs in up to 30% of patients with psoriasis, most commonly those
aged between 30 and 60 years. The symptom burden of PsA can have a
substantial negative impact on patient quality of life. Although
the exact mechanism of disease is not fully understood, evidence
suggests that activation of the IL-17 pathway plays an important
role in the disease pathophysiology.
Cautionary Statement Regarding Forward
Looking Statements
This press release contains certain
“forward-looking statements” within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements include, but are not limited to, statements regarding
MoonLake’s expectations, hopes, beliefs, intentions or strategies
regarding the future including, without limitation, statements
regarding: plans for and timing of clinical trials, including
initiation of Phase 3 VELA TEEN trial of sonelokimab in adolescents
with HS, commencement of clinical trials of sonelokimab in PPP,
axSpA and topline results of the Phase 3 VELA program of
sonelokimab in HS, the efficacy and safety of sonelokimab for the
treatment of HS and PsA, including in comparison to existing
standards or care or other competing therapies, clinical trials and
research and development programs and the anticipated timing of the
results from those studies and trials, potential market
opportunities for sonelokimab and our anticipated cash usage and
the period of time we anticipate such cash to be available. In
addition, any statements that refer to projections, forecasts, or
other characterizations of future events or circumstances,
including any underlying assumptions, are forward- looking
statements. The words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,”
“potential,” “predict,” “project,” “should,” “would” and similar
expressions may identify forward-looking statements, but the
absence of these words does not mean that statement is not forward
looking.
Forward-looking statements are based on current
expectations and assumptions that, while considered reasonable by
MoonLake and its management, as the case may be, are inherently
uncertain. New risks and uncertainties may emerge from time to
time, and it is not possible to predict all risks and
uncertainties. Actual results could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include, without limitation,
risks and uncertainties associated with MoonLake’s business in
general and limited operating history, difficulty enrolling
patients in clinical trials, state and federal healthcare reform
measures that could result in reduced demand for MoonLake’s product
candidates and reliance on third parties to conduct and support its
preclinical studies and clinical trials and the other risks
described in or incorporated by reference into MoonLake’s Annual
Report on Form 10-K for the year ended December 31, 2023 and
subsequent filings with the Securities and Exchange Commission.
Nothing in this press release should be regarded
as a representation by any person that the forward-looking
statements set forth herein will be achieved or that any of the
contemplated results of such forward-looking statements will be
achieved. You should not place undue reliance on forward-looking
statements in this press release, which speak only as of the date
they are made and are qualified in their entirety by reference to
the cautionary statements herein. MoonLake does not undertake or
accept any duty to release publicly any updates or revisions to any
forward-looking statements to reflect any change in its
expectations or in the events, conditions or circumstances on which
any such statement is based.
CONTACT
MoonLake Immunotherapeutics
InvestorsMatthias Bodenstedt, CFOir@moonlaketx.com
MoonLake Immunotherapeutics
MediaPatricia Sousa, Director Corporate
Affairsmedia@moonlaketx.com
ICR Consilium Mary-Jane
Elliott, Ashley Tapp, Namrata TaakTel: +44 (0) 20 3709
5700MoonLake@consilium-comms.com
MOONLAKE
IMMUNOTHERAPEUTICSCONDENSED CONSOLIDATED BALANCE
SHEETS
(Amounts in USD, except share data)
|
|
June 30, 2024 (Unaudited) |
|
December 31.2023 |
Current
assets |
|
|
|
|
Cash and cash equivalents |
|
$ 342,791,142 |
|
$ 451,169,337 |
Short-term marketable debt securities |
|
177,008,400 |
|
59,838,900 |
Other receivables |
|
1,676,813 |
|
1,056,862 |
Prepaid expenses - current |
|
15,405,526 |
|
2,102,203 |
Total
current assets |
|
536,881,881 |
|
514,167,302 |
|
|
|
|
|
Non-current assets |
|
|
|
|
Operating lease right-of-use assets |
|
3,384,953 |
|
3,628,480 |
Property and equipment, net |
|
481,705 |
|
320,865 |
Prepaid expenses - non-current |
|
4,129,151 |
|
8,423,468 |
Total
non-current assets |
|
7,995,809 |
|
12,372,813 |
Total
assets |
|
$ 544,877,690 |
|
$ 526,540,115 |
|
|
|
|
|
Current
liabilities |
|
|
|
|
Trade and other payables |
|
$ 5,142,853 |
|
$ 1,837,684 |
Short-term portion of operating lease liabilities |
|
1,321,727 |
|
1,197,876 |
Accrued expenses and other current liabilities |
|
5,817,384 |
|
6,930,120 |
Total
current liabilities |
|
12,281,964 |
|
9,965,680 |
|
|
|
|
|
Non-current liabilities |
|
|
|
|
Long-term portion of operating lease liabilities |
|
2,022,280 |
|
2,499,990 |
Pension liability |
|
541,949 |
|
583,426 |
Total
non-current liabilities |
|
2,564,229 |
|
3,083,416 |
Total
liabilities |
|
14,846,193 |
|
13,049,096 |
Commitments and
contingencies (Note 15) |
|
|
|
|
|
|
|
|
|
Equity |
|
|
|
|
Class A Ordinary Shares: $0.0001 par value; 500,000,000 shares
authorized; 62,874,637 shares issued and outstanding as of
June 30, 2024; 60,466,453 shares issued and outstanding as of
December 31, 2023 |
|
6,287 |
|
6,047 |
Class C Ordinary Shares: $0.0001 par value; 100,000,000 shares
authorized; 995,267 shares issued and outstanding as of
June 30, 2024; 2,505,476 shares issued and outstanding as of
December 31, 2023 |
|
100 |
|
251 |
Additional paid-in capital |
|
671,998,583 |
|
609,969,236 |
Accumulated deficit |
|
(154,598,140) |
|
(116,657,472) |
Accumulated other comprehensive income |
|
3,256,907 |
|
2,357,621 |
Total
shareholders’ equity |
|
520,663,737 |
|
495,675,683 |
Noncontrolling interests |
|
9,367,760 |
|
17,815,336 |
Total
equity |
|
530,031,497 |
|
513,491,019 |
Total
liabilities and equity |
|
$ 544,877,690 |
|
$ 526,540,115 |
|
|
|
|
|
|
|
|
|
|
MOONLAKE
IMMUNOTHERAPEUTICSCONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE
LOSS(Unaudited)
(Amounts in USD, except share and per share
data)
|
|
For the Three Months Period Ended |
|
|
June 30, |
|
March 31, |
|
|
2024 |
|
2024 |
Operating
expenses |
|
|
|
|
Research and development |
|
$ (23,662,147) |
|
$ (13,014,049) |
General and administrative |
|
(6,916,054) |
|
(6,806,440) |
Total
operating expenses |
|
(30,578,201) |
|
(19,820,489) |
Operating
loss |
|
(30,578,201) |
|
(19,820,489) |
|
|
|
|
|
Other income, net |
|
5,898,148 |
|
5,915,220 |
Loss
before income tax |
|
(24,680,053) |
|
(13,905,269) |
|
|
|
|
|
Income tax expense |
|
(78,701) |
|
(70,252) |
Net
loss |
|
$ (24,758,754) |
|
$ (13,975,521) |
Of which: net loss attributable to controlling interests
shareholders |
|
(24,267,012) |
|
(13,673,656) |
Of which: net loss attributable to noncontrolling interests
shareholders |
|
(491,742) |
|
(301,865) |
|
|
|
|
|
Net unrealized gain (loss) on marketable securities and short term
investments |
|
652,097 |
|
182,273 |
Actuarial gain (loss) on employee benefit plans |
|
(76,479) |
|
81,230 |
Other
comprehensive income (loss) |
|
575,618 |
|
263,503 |
Comprehensive loss |
|
$ (24,183,136) |
|
$ (13,712,018) |
Comprehensive loss attributable to controlling interests
shareholders |
|
(23,703,201) |
|
(13,415,707) |
Comprehensive loss attributable to noncontrolling interests |
|
(479,935) |
|
(296,311) |
|
|
|
|
|
Weighted-average
number of Class A Ordinary Shares, basic and diluted |
|
62,874,637 |
|
62,637,212 |
Basic and
diluted net loss per share attributable to controlling interests
shareholders |
|
$ (0.39) |
|
$ (0.22) |
MoonLake Immunotherapeut... (NASDAQ:MLTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
MoonLake Immunotherapeut... (NASDAQ:MLTX)
Historical Stock Chart
From Aug 2023 to Aug 2024